Genitrix has announced that HY-50 Vet, a sodium hyaluronate treatmentfor equine joints, has now been authorised for intravenous (IV) use.
Previously available for intra-articular (IA) use only, HY-50 is said to deliver the highest concentration of sodium hyaluronate on the market for the treatment of non-infectious joint inflammation and the enhancement of joint function.
Genitrix says that, as IV application requires less specialist preparation than IA, HY-50 is now a practical solution for mixed practices with a smaller equine case load. Injected intravenously, the product will also benefit horses with multiple joint injuries.
HY-50 is presented in a 3 ml pre-loaded syringe, delivering 50 mg of sodium hyaluronate. It costs £55.50.
Genitrix marketing director Rob Watkins said: “The efficacy of sodium hyaluronate is well established and we’re delighted to be able to offer the IV route of administration. We know it will meet a real need in the market for a lameness treatment which is proven and simple to administer.
“Perhaps most importantly, in these financially difficult times, we believe it will offer an affordable treatment option for owners who are anxious to treat their horses but may be discouraged by the high cost of many treatments.”
For further information, visit www.genitrix.co.uk or contact them on 01403 786345.